CRISPR Therapeutics AG
CRISPR Therapeutics AG, a pioneering biotechnology company headquartered in Switzerland (CH), is at the forefront of gene editing innovation. Founded in 2013, the company focuses on developing transformative therapies using its proprietary CRISPR/Cas9 technology, which allows for precise modifications to DNA.
With a strong presence in Europe and North America, CRISPR Therapeutics is dedicated to addressing serious diseases, particularly in the fields of oncology, regenerative medicine, and genetic disorders. Its lead product candidates, including CTX001 for sickle cell disease and beta-thalassemia, exemplify the unique potential of CRISPR technology to provide curative solutions.
Recognised for its significant contributions to the industry, CRISPR Therapeutics AG continues to solidify its market position through strategic partnerships and groundbreaking research, making it a key player in the rapidly evolving landscape of gene editing therapies.
-15 vs industry average
CRISPR Therapeutics AG’s score of 23 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at CRISPR Therapeutics AG?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for CRISPR Therapeutics AG yet.
CRISPR Therapeutics AG's reported carbon emissions
CRISPR Therapeutics AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse.
In terms of climate commitments, CRISPR Therapeutics AG has not outlined any formal reduction targets or initiatives. There are no details available regarding Science-Based Targets Initiative (SBTi) commitments or other climate pledges. This lack of publicly available data suggests that the company may still be in the early stages of developing a comprehensive climate strategy.
As the biotechnology industry increasingly prioritises sustainability, CRISPR Therapeutics AG's future climate commitments will be crucial for aligning with industry standards and expectations.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
CRISPR Therapeutics AG’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for CRISPR Therapeutics AG yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
CRISPR Therapeutics AG
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project